TherapeuticsMD (TXMD) Net Income towards Common Stockholders (2010 - 2026)
TherapeuticsMD (TXMD) posted Net Income towards Common Stockholders of -$8000.0 for Q1 2026, down 14.29% on a QoQ basis from -$7000.0 in Q4 2025, and up 52.94% year-over-year from -$5230.8 in Q1 2025.
TherapeuticsMD (TXMD) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
TherapeuticsMD's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$8000.0 for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 52.94% year-over-year to -$8000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93000.0 (up 138.46% YoY) and the FY2025 annual result came in at $84000.0, down 35.88% from the prior year.
- Net Income towards Common Stockholders was -$8000.0 for Q1 2026 at TherapeuticsMD, down from -$7000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $127.2 million in Q2 2022 and bottomed at -$31.1 million in Q1 2022.
- A 5-year average of $6.8 million and a median of -$7500.0 in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 398.12% — and 2025, when it sank 122.67%.
- TherapeuticsMD's Net Income towards Common Stockholders stood at $29.2 million in 2022, then slumped by 97.75% to $658000.0 in 2023, then tumbled by 79.03% to $138000.0 in 2024, then slumped by 105.07% to -$7000.0 in 2025, then dropped by 14.29% to -$8000.0 in 2026.
- Business Quant data shows TXMD's Net Income towards Common Stockholders at -$8000.0 in Q1 2026, -$7000.0 in Q4 2025, and $102000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | TherapeuticsMD | 280,418.39 | -8.14 Mn | - | -8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | -17,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Sep 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -40,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | 658,000.00 |
| Sep 30, 2023 | -1.94 Mn |
| Mar 31, 2023 | -1.29 Mn |
| Dec 31, 2022 | 29.25 Mn |
| Sep 30, 2022 | -14.33 Mn |
| Jun 30, 2022 | 127.15 Mn |
| Mar 31, 2022 | -31.15 Mn |
| Dec 31, 2021 | 50.15 Mn |
| Sep 30, 2021 | -47.42 Mn |
| Jun 30, 2021 | -42.65 Mn |
| Mar 31, 2021 | -39.38 Mn |